Stock Ticker

  • Loading stock data...

The European Union Approves Johnson & Johnson (NYSE:JNJ) Vaccine

Johnson & Johnson (NYSE:JNJ) has disclosed the European Union’s move to approve its vaccine. The bloc’s executive arm under the European Commission authorized the vaccine despite the endless global wars over vaccines.

Storage and usage

The Johnson & Johnson vaccine’s storage is relatively easy, considering the European Commission’s recommendation for storage in regular fridges. According to the body, the product could last up to three months in fridges. The body also outlined that users needed only to take a single shot of the vaccine.

The regulatory body had earlier approved three other vaccines, and the Johnson & Johnson vaccine pulls in as the fourth one. The body continues reviewing more products to consider if they pass the tests. Some of the vaccines under scrutiny include Sputnik V, Novavax, and CureVac. The body discloses that all the above products are in the preliminary stage and might approve all these products.

The latest move means well for the European Union, which will receive about 200 million doses of the Johnson & Johnson vaccine. The contract in question gives a leeway for the European Union to order 200 million more of the Johnson & Johnson vaccine.

Vaccination efforts

The bloc’s vaccination efforts have over the past moved sluggishly, but that might soon be changing with the latest supplies in place. Reports show the inoculation having covered only about 6.5% out of a total of 450 million residents in the European Union. The above-stipulated figure lags behind the numbers pronounced in Israel, Britain, and the United States.

The Johnson & Johnson vaccine will be shipped to Europe and will arrive in April. The bloc faces pressure, with the warring parties complaining about how it has been going about its export restriction moves.

It was in the previous week that Italy blocked a shipment of doses to Australia. The whole thing had to do with “vaccine nationalism,” which is becoming a matter of great concern.

The contractual arrangement between vaccine producers, the E.U., and the conformity is a guideline matter, and it determines who receives approval and who doesn’t.

Published by Chris Brown

About Me: I have a Phd in Economics Gender: Male Interests: Playing games like cricket, volleyball Favorite Music: hip hop, rock, jazz

Recent Stories

SignUp Now For Our Featured Newsletter